Now showing items 1-20 of 54

    • 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. 

      Passamonti, Luca; Vázquez, Rodríguez Patricia; Hong, Young Tea; Allinson, Kieren SJ; Williamson, David; Borchert, Robin J; Sami, Saber et al. (Oxford Academic, 2017-03)
      The ability to assess the distribution and extent of tau pathology in Alzheimer's disease and progressive supranuclear palsy in vivo would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying ...
    • [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia 

      Bevan-Jones, William Richard; Cope, Thomas Edmund; Jones, PS; Passamonti, Luca; Hong, Young Tea; Fryer, Timothy David; Arnold, R et al.
      Introduction Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA), is strongly associated with TAR-DNA binding protein 43 (TDP-43) type C pathology. It provides a useful model in which ...
    • [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia 

      Bevan-Jones, William Richard; Cope, Thomas Edmund; Jones, PS; Passamonti, Luca; Hong, Young Tea; Fryer, Timothy David; Arnold, R et al.
      Introduction Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA), is strongly associated with TAR-DNA binding protein 43 (TDP-43) type C pathology. It provides a useful model in which ...
    • [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia 

      Bevan-Jones, William Richard; Cope, Thomas Edmund; Jones, PS; Passamonti, Luca; Hong, Young Tea; Fryer, Timothy David; Arnold, R et al.
      INTRODUCTION: Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA), is strongly associated with TAR-DNA binding protein 43 (TDP-43) type C pathology. It provides a useful model in which ...
    • [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation 

      Bevan Jones, WR; Cope, Thomas Edmund; Passamonti, Luca; Fryer, Timothy David; Hong, Young Tea; Aigbirhio, Franklin Imo; Kril, JJ et al. (Wiley, 2016-12)
      The validation of tau radioligands could improve the diagnosis of frontotemporal lobar degeneration and the assessment of disease-modifying therapies. Here, we demonstrate that binding of the tau radioligand [$^{18}$F]AV-1451 ...
    • 7T MRI for neurodegenerative dementias in vivo: a systematic review of the literature. 

      McKiernan, Elizabeth Frances; O'Brien, John Tiernan (BMJ Publishing, 2017-07)
      The spatial resolution of 7T MRI approaches the scale of pathologies of interest in degenerative brain diseases, such as amyloid plaques and changes in cortical layers and subcortical nuclei. It may reveal new information ...
    • Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. 

      Thomas, Alan J; Attems, Johannes; Colloby, Sean J; O'Brien, John Tiernan; McKeith, Ian; Walker, Rodney; Lee, Lean et al. (2017-01)
    • Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study 

      Mak, Elijah; Su, Li; Williams, Guy Barnett; Firbank, Michael J; Lawson, Rachel A; Yarnall, Alison J; Duncan, Gordon W et al. (Oxford University Press, 2015-07-14)
      Mild cognitive impairment in Parkinson’s disease is associated with progression to dementia (Parkinson’s disease dementia) in a majority of patients. Determining structural imaging biomarkers associated with prodromal ...
    • Cerebral small vessel disease in middle age and genetic predisposition to late-onset Alzheimer's disease. 

      Stefaniak, James D; Su, Li; Mak, Elijah; Sheikh-Bahaei, Nasim; Wells, Katie; Ritchie, Karen; Waldman, Adam et al. (Elsevier, 2017-11-18)
      INTRODUCTION: Cerebral small vessel disease (CSVD) is associated with late-onset Alzheimer’s Disease (LOAD), and might contribute to the relationship between APOEє4 and LOAD, in older people. However, it is unclear whether ...
    • Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology 

      O'Brien, John Tiernan; Holmes, C; Jones, M; Jones, R; Livingston, G; McKeith, I; Mittler, P et al. (SAGE, 2017-02-01)
      The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated ...
    • Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. 

      Webster, L; Groskreutz, D; Grinbergs-Saull, A; Howard, R; O'Brien, John Tiernan; Mountain, G; Banerjee, S et al. (PloS, 2017-06-29)
      BACKGROUND: There are no disease-modifying treatments for dementia. There is also no consensus on disease modifying outcomes. We aimed to produce the first evidence-based consensus on core outcome measures for trials of ...
    • Cortical and subcortical changes in Alzheimer’s disease: a longitudinal and quantitative MRI study 

      Su, Li; Blamire, Andrew M; Watson, Rosie; He, Jiabao; Aribisala, Benjamin; O'Brien, John Tiernan (2015-11-16)
    • Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 

      Webster, Lucy; Groskreutz, Derek; Grinbergs-Saull, Anna; Howard, Rob; O'Brien, John Tiernan; Mountain, Gail; Banerjee, Sube et al. (2017-05)
    • Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. 

      Thomas, Alan J; Taylor, John Paul; McKeith, Ian; Bamford, Claire; Burn, David; Allan, Louise; O'Brien, John Tiernan (Wiley, 2016-12-08)
      $\textbf{Objective:}$ The Lewy body dementias (LBD, dementia with Lewy bodies and Parkinson's disease dementia) are the second most common cause of neurodegenerative dementia but remain under-recognised, with long delays ...
    • Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium 

      McKeith, IG; Boeve, BF; Dickson, DW; Halliday, G; Taylor, J-P; Weintraub, D; Aarsland, D et al. (2017-06-07)
      The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The ...
    • Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease 

      Kobeleva, X; Firbank, M; Peraza, L; Gallagher, P; Thomas, A; Burn, DJ; O'Brien, John Tiernan et al. (Elsevier, 2017-03-18)
      Attention and executive dysfunction are features of Lewy body dementia (LBD) but their neuroanatomical basis is poorly understood. To investigate underlying dysfunctional attention-executive network (EXEC) interactions, ...
    • Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies? 

      Watson, Rosie; Colloby, Sean J; Blamire, Andrew M; Wesnes, Keith A; Wood, Josh; O'Brien, John Tiernan (Elsevier, 2017-12)
      Introduction To evaluate the clinical characteristics of DLB subjects who died within 1 year of assessment compared to those who survived and investigate their patterns of in vivo regional thalamic atrophy using structural ...
    • DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT 

      Jones, Rob; Sheehan, Bart; Phillips, Patrick; Juszczak, Ed; Adams, Jessica; Baldwin, Ashley; Ballard, Clive et al. (2009-07-24)
    • Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease 

      Habib, M; Mak, E; Gabel, S; Su, Li; Williams, Guy Barnett; Waldman, A; Wells, K et al. (Elsevier, 2017-07-01)
      It is well established that the neurodegenerative process of Alzheimer's disease (AD) begins many years before symptom onset. This preclinical phase provides a crucial time-window for therapeutic intervention, though this ...
    • Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study 

      Nombela, Cristina; Rowe, James Benedict; Winder-Rhodes, Sophie E; Hampshire, Adam; Owen, Adrian M; Breen, David P; Duncan, Gordon W et al. (Oxford University Press, 2014-07-30)
      Parkinson’s disease is associated with multiple cognitive impairments and increased risk of dementia, but the extent of these deficits varies widely among patients. The ICICLE-PD study was established to define the ...